Skip to main content
. 2017 Mar 20;28(6):1294–1301. doi: 10.1093/annonc/mdx112

Figure 2.

Figure 2.

Mutant allele fraction analysis. (A) RAS mutant allele fractions in ctDNA BEAMing, a MAF of 0.01 corresponds to a percentage of mutant alleles of 1%. (B) Comparison of RAS mutant allele fractions in ctDNA and positivity for RAS mut tumor by SoC testing. (C) Correlation of RAS mutant allele fractions with BEAMing carried out in tumor (adjusted for purity) and ctDNA, according to prior systemic therapy exposure. Samples with RAS wild-type by SoC were excluded. (D) Correlation of RAS mutant allele fractions with BEAMing carried out in tumor (adjusted for purity) and ctDNA, according to number of metastatic sites. Samples with RAS wild-type by SoC were excluded. mut, mutation SoC, standard of care.